Enhancing Depression Literacy and Reducing Stigma in Adolescents Through Social Media
Launched by LUDWIG-MAXIMILIANS - UNIVERSITY OF MUNICH · Jul 10, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This study is looking at whether using an Instagram channel called "ich bin alles" ("I am everything") can help teenagers learn more about depression, reduce negative feelings or stigma around it, and encourage them to seek help if they need it. Depression is common among young people but often goes unrecognized or untreated because many don’t know enough about it or are afraid of being judged. Since teens spend a lot of time on social media, this project shares easy-to-understand and trustworthy information about depression and mental health through digital platforms like Instagram.
To join the study, participants need to be regular Instagram users and have their own Instagram account. The study is open to people of all genders within the age range of 47 to 74 years old. Participants will engage with the Instagram content and the researchers will look at how well the channel helps improve understanding of depression, lowers stigma, and influences whether people are more willing to seek help. The study is currently recruiting participants, and there are no other restrictions for joining.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ownership of an Instagram account
- • Regular use of Instagram
- Exclusion Criteria:
- • No exclusion citeria
About Ludwig Maximilians University Of Munich
Ludwig-Maximilians-University of Munich (LMU Munich) is a prestigious research institution in Germany, renowned for its commitment to advancing medical science and improving patient care through innovative clinical research. As a leading sponsor of clinical trials, LMU Munich leverages its extensive academic resources and interdisciplinary expertise to conduct rigorous studies aimed at evaluating new therapeutic interventions and advancing healthcare knowledge. The university fosters collaboration among researchers, clinicians, and healthcare professionals, ensuring that trials are designed and executed with the highest ethical standards and scientific integrity. Through its dedication to excellence in research, LMU Munich aims to contribute significantly to the development of effective treatments and enhance the overall health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, Bavaria, Germany
Patients applied
Trial Officials
Gerd Schulte-Körne, Prof. Dr.
Principal Investigator
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Hospital of the Ludwig-Maximilians-University (LMU) Munich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported